Samstag, 7. Dezember 2019
Navigation öffnen


PREPARE Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib



Januar 2017

Letztes Update:


Indikation (Clinical Trials):
Carcinoma, Carcinoma, Renal Cell


Erwachsene (18+)

Phase 3


Pfizer, Celerion,


Viktor Grünwald, Prof. Dr.
Principal Investigator
Universitätsklinikum Essen


Aysun Karatas, Dr.
Phone: +49 30 8145 344
Phone (ext.): 31
» Kontaktdaten anzeigen
Markus Detzner
Phone: +49 30 8145344
Phone (ext.): 52
» Kontaktdaten anzeigen

Studienlocations (3 von 20)

Gemeinschaftspraxis Dr. med. Johannes Mohm Dr. med. Gabriele Prange Krex Fachärzte für Innere Medizin Hämatologie und Internistische Onkologie
01307 Dresden
GermanyNoch nicht rekrutierend» Google-Maps
Johannes Mohm, Dr. med.
» Ansprechpartner anzeigen
Leberkrebszentrum Medizinische Hochschule Hannover
Carl-Neuberg-Straße 1
30625 Hannover
DeutschlandRekrutierend» Google-Maps
Philipp Ivanyi, Dr.
Phone: +49 511 532
Phone (ext.): 2301
» Ansprechpartner anzeigen
IDGGQ Institut für medizinische Dokumentation, Gutachtenerstellung, Gesundheitsförderung u. Qualitätssicherung
67655 Kaiserslautern
GermanyNoch nicht rekrutierend» Google-Maps
Richard Hansen, Dr. med.
» Ansprechpartner anzeigen
Gemeinschaftspraxis für Hämatologie u. Onkologie PD Dr. Jan Schröder
45468 Mühlheim
GermanyNoch nicht rekrutierend» Google-Maps
Jan Schröder, PD Dr.
» Ansprechpartner anzeigen
Kinderonkologisches Zentrum am Universitätsklinikum Münster
Albert-Schweitzer-Campus 1
48149 Münster
DeutschlandNoch nicht rekrutierend» Google-Maps
Martin Bögemann, PD Dr.
» Ansprechpartner anzeigen
Alle anzeigen


Detailed Description:

The goal of our study is to define the benefit of proactive coaching in mRCC, when compared to a reactive approach, which is considered the standard of care.

Patients in the Coaching Arm A will be trained continuously at personal interactions of coach and patient (Face-to Face meetings as well as telephone contacts). The patient is educated on nature and severity of treatment emergent Adverse events (TEAE) of the Sunitinib-Therapy.

Quality of Life (QoL) is assessed during sunitinib treatment in both arms (Arm A Coaching and Arm B non Coaching).


Inclusion Criteria:

1. Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations

2. Age ≥ 18 years at time of study entry

3. Advanced or metastatic renal cell carcinoma, not amendable to surgery with curative intent, rendering the patient eligible for Tyrosin Kinase Inhibitor (TKI) treatment with sunitinib

4. Intended first-line treatment with sunitinib

5. Documented progressive disease within 6 months prior to study inclusion

6. Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as well as non-measurable disease are eligible.

7. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and patient recovered from toxic effects.

8. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

9. Subject is willing to receive additional concomitant coaching and able to comply with the QoL/PRO (patient-reported outcome) assessments specified in the protocol for the duration of the study including scheduled visits, examinations and follow up.

Exclusion Criteria:

1. Any other anti-cancer treatment aside of sunitinib for mRCC (except palliative radiotherapy)

2. Previous malignancy (other than mRCC) which either progresses or requires active treatment.

Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].

3. CNS metastases, unless local therapy has been completed for at least 3 month and patient does not require the use of steroids.

4. Chronic liver disease with Child-Pugh B or C score

5. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year)

6. Any condition that, in the opinion of the investigator, would interfere with evaluation of the concomitant coaching or QoL assessments or interpretation of patient safety or study results

7. Participation in another clinical study with an investigational product during the last 30 days before inclusion

8. Any previous treatment with a tyrosine kinase inhibitor for metastatic disease. Adjuvant or neoadjuvant therapy for localized disease is permitted, provided that relapse occurred at least 6 months after last exposure

9. Previous enrollment or randomization in the present study (does not include screening failure).

10. Involvement in the planning and/or conduct of the study (applies to both Pfizer staff and/or staff of sponsor and study site)

11. Patient who might be affiliated or otherwise dependent on the sponsor, site or the investigator

12. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities [§ 40 Abs. 1 S. 3 Nr. 4 AMG].

13. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].


Primary outcome:

1. QoL assessment during sunitinib treatment: questionnaire (Time Frame - 24 weeks from randomization):
Rate of responders to concomitant coaching assessed by the (Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)) FKSI-15 questionnaire.

Secondary outcome:

1. Objective Response Rate (ORR) according to RECIST 1.1 criteria (Time Frame - up to one year from randomization):
Objective Response Rate (ORR) according to RECIST 1.1 criteria

2. Overall Survival (OS) (Time Frame - up to 36 months from randomization):
Overall Survival (OS)

3. progression-free survival (PFS) (Time Frame - up to 36 months from randomization):
progression-free survival (PFS)

4. Duration of treatment (coaching and cancer treatment) (Time Frame - Coaching: up to 24 weeks from randomization / cancer treatment: up to 36 months from randomization):
Duration of treatment (coaching and cancer treatment)

5. dose density of sunitinib (Time Frame - 24 weeks from randomization):
dose density of sunitinib

6. Rate of patients receiving treatment beyond progression (Time Frame - up to 36 months from randomization):
Rate of patients receiving treatment beyond progression

7. Further cancer treatment (Time Frame - up to 36 months):
Further cancer treatment

8. Time to first subsequent therapy (TFST) (Time Frame - up to 36 months):
Time to first subsequent therapy (TFST)

9. Patient adherence / treatment discontinuation due to Adverse drug reactions (ADRs) / Serious adverse events (SAEs): (Time Frame - 24 weeks from randomization):
% of patients with treatment discontinuation due to specific ADRs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension)

10. Treatment Emergent Adverse Events according to CTC 4.03: (Time Frame - 24 weeks from randomization):
Frequency/incidence, severity, percentage reduction, time-to-event of ADRs, AEs and specific TEAEs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension) change of grade 3/4 ADRs

11. Assessment of comorbidities (Time Frame - at inclusion):
Charlson Comorbidity Index (CCI)


  • Experimental: Arm A (Coaching)
    Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
  • No Intervention: Arm B (Control)
    Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15

Geprüfte Regime

  • Concomitant coaching:
    The corner stones of the pro-active coaching are as follows: Patient education: Information on nature and severity of treatment emergent AEs information about remedies for TEAEs propagation and explanation of tests and treatment decisions Patient instruction on self-care and preventive measures Preemptive AE treatment strategies Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach


Das könnte Sie auch interessieren

HPV-Impfung schützt vor Krebs

HPV-Impfung schützt vor Krebs
© pixelaway -

Krebsprävention ist eine zentrale Strategie im Kampf gegen Krebs. Zur Prävention zählen auch Impfungen, mit denen vielen Krebserkrankungen gezielt vorgebeugt werden kann. Beispiel: Humane Papillomviren (HPV), deren Hochrisiko-Typen für Gebärmutterhalskrebs und andere Krebserkrankungen verantwortlich sind. Doch es gibt eine wirksame und gut verträgliche Impfung, die vor der Infektion mit HPV schützt und der Entwicklung von Krebs vorbeugt. Wer sollte sich...